

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

LIRAGLUTIDE FOR MANAGING OVERWEIGHT AND OBESITY, NICE TA664, DECEMBER 2020

**RED – RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALIST
MULTIDISCIPLINARY TIER 3 WEIGHT MANAGEMENT SERVICE ONLY.
NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING**

Name: generic (trade)	What it is	Licensed indications	Decision status	NICE guidance
LIRAGLUTIDE s/c injection (Saxenda®)	GLP-1 analogue	Adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of ≥ 30 kg/m ² (obese) or ≥ 27 kg/m ² to < 30 kg/m ² (overweight) in the presence of at least one weight-related co-morbidity	Final	NICE TA664 – recommended

MSEMOC recommendation:

Liraglutide is recommended as an option for managing overweight and obesity in adults in accordance with NICE technology appraisal recommendations.

[NICE TA664](#) recommendation:

1.1 Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, only if:

- they have a body mass index (BMI) of at least 35 kg/m² (or at least 32.5 kg/m² for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and
- they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) and
- they have a high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia and
- it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service and
- the company provides it according to the commercial arrangement.

1.2 This recommendation is not intended to affect treatment with liraglutide that was started in the NHS before this guidance was published. Adults having treatment outside this recommendation may continue without changes to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Background information and extracts from the NICE TA

- The manufacturer has confirmed that the commercial arrangement is only available through a trust (hospital) where there is a specialist tier 3 weight management service
- The clinical experts (In the NICE TA) explained that long-term weight loss would not be achieved without the ongoing and psychological support that is a feature of tier 3 services.
- Liraglutide (Saxenda®) is a different licensed product to liraglutide (Victoza®) and the doses of liraglutide (Saxenda®) used for weight management are different to that used in managing type 2 diabetes (Victoza®).
- Currently, all GLP-1 receptor analogue products apart from Saxenda® are NOT licensed as treatment options for weight management. Therefore, apart from Saxenda® (in line with the NICE TA) all other GLP-1 receptor agonists are NOT RECOMMENDED as a treatment for weight management.

For further information refer to the [Summary of Product Characteristics for liraglutide \(Saxenda®\)](#).



Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA664: Liraglutide for managing overweight and obesity: https://www.nice.org.uk/guidance/ta664
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC; MSE Joint Committee
Date Approved	February 2021; February 2021
Review Date	February 2026 or sooner if subject to any new updates nationally